Last reviewed · How we verify
NCT04941573
Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI
trial testing Hyperpolarized 129-Xenon (MagniXene) MRI of the lung in Lung Transplant Rejection in 45 participants. Terminated before completion.
4 September 2025
Quick facts
| Lead sponsor | Xemed LLC |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 45 |
| Start date | 19 January 2021 |
| Primary completion | 4 September 2025 |
| Estimated completion | 4 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Conditions studied
- Lung Transplant Rejection — all drugs for Lung Transplant Rejection →
Sponsor
Xemed LLC — full company profile →
Who can join
Adults 18 to 80, any sex, with Lung Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will use Magnetic Resonance Imaging (MRI) to study the lungs of 90 volunteers using the inhaled contrast agent, hyperpolarized xenon-129. Once inhaled, this gas can provide information to imagers regarding lung functionality across specific regions of the lungs by assessing the replacement of air during the normal breathing cycle, how much oxygen is in the airspaces, and if the natural spongy tissue structure has been compromised by lung disease. Of the 90 subjects, 70 will be patients who received lung transplantation from the Penn/Temple Lung Transplant Teams and are receiving follow up treatment at HUP or TUH, 10 will be healthy control subjects who participated favorably in our HP 129Xe imaging protocol, and 10 will be patients who have been diagnosed with chronic obstructive pulmonary disease (COPD)-preferentially recruited from the Temple University COPDGene cohort, who have never undergone a lung transplant. 20 of the lung transplant recipient subjects will be patients who have received a recent clinical diagnosis of chronic lung allograft dysfunction (CLAD) prior to enrollment in our study, while the other 50 will have recently undergone their initial transplant surgery at the time of enrollment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04941573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Transplant Rejection
Currently open trials in the same condition.
- NCT06824402 — Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients · NA · recruiting
- NCT06399302 — Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes · recruiting
- NCT06112951 — A Prospective Randomized Trial of ECP in Subclinical AMR · NA · recruiting
- NCT06082037 — A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfun · Phase 3 · recruiting
- NCT06514378 — Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction · Phase 1 · recruiting
Other Xemed LLC trials
Trials by the same sponsor.
- NCT04035629 — 129Xe MRI in Pediatric Population With BPD · Phase 1 · withdrawn
- NCT07355231 — Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI · Phase 1, PHASE2 · not yet recruiting
- NCT05816616 — Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation · withdrawn
- NCT05433961 — Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI · Phase 1 · terminated
- NCT05302817 — Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04941573 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xemed LLC
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04941573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing